Accès à distance ? S'identifier sur le proxy UCLouvain
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
Primary tabs
Document type | Article de périodique (Journal article) – Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't |
---|---|
Access type | Accès restreint |
Publication date | 2005 |
Journal information | "Blood" - Vol. 106, no. 8, p. 2646-54 (2005) |
Peer reviewed | yes |
issn | 0006-4971 |
Publication status | Publié |
Affiliations |
UCL
- MED - Sciences médicales UCL - MD/MINT - Département de médecine interne UCL - (SLuc) Service d'hématologie |
MESH Subject | Aged ; Aged, 80 and over ; Cyclosporins - adverse effects - therapeutic use ; Cytarabine - adverse effects - therapeutic use ; Daunorubicin - adverse effects - therapeutic use ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myeloid, Acute - diagnosis - drug therapy - metabolism ; Male ; Middle Aged ; P-Glycoprotein - metabolism ; Survival Rate ; Treatment Outcome |
Links |
Bibliographic reference | van der Holt, Bronno ; Löwenberg, Bob ; Burnett, Alan K ; Knauf, Wolfgang U ; Shepherd, John ; et. al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.. In: Blood, Vol. 106, no. 8, p. 2646-54 (2005) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/26950 |